Interim estimated effectiveness of 2025-2026 COVID-19 vaccines in adults using a test-negative design
Peer-Reviewed Publication
This September, we're exploring the science behind vaccines. From how they train our immune systems to fight disease to the research shaping their future, vaccines offer an opportunity to discover the science helping protect individuals and communities around the world.
Updates every hour. Last Updated: 20-Oct-2026 18:16 ET (20-Oct-2026 22:16 GMT/UTC)
Genital herpes is a lifelong infection. While available treatments can manage symptoms, they cannot cure the infection or prevent transmission. Now, Yale School of Medicine researchers have taken a significant step toward a genital herpes vaccine that in preclinical models prevented infection.
In a study published June 19 in Science Immunology, researchers evaluated a two-part vaccination against genital herpes. With the technique, the first part — a typical intramuscular injection like you would receive for a flu shot, for example — is followed by the introduction of nanoparticles to the vagina, where herpes infection occurs in women.
The idea is the initial injection “primes” the immune system while the second localized treatment “pulls” immune activity right to where infection takes place. This study extends the original “prime and pull” approach by developing a new nanoparticle that effectively induces local immunity.
“We’ve found that, in preclinical experiments, this approach is a safe way to recruit the right immune cells in the right place to generate protective immunity,” said senior author Akiko Iwasaki, Sterling Professor of Immunobiology at Yale School of Medicine.- Prof. Sangmin Lee of POSTECH publishes findings in Nature, the world's most prestigious academic journal, through joint research with Prof. David Baker of the University of Washington, Nobel Prize laureate.
- Viral structural principles reproduced using AI, with promising applications as next-generation drug delivery systems.